申请人:Shire Human Genetic Therapies, Inc.
公开号:US20210078999A1
公开(公告)日:2021-03-18
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物及其组合物。